NCT06303037View on ClinicalTrials.gov

Effect of Esketamine on 95% Induction Dose of Remimazolam

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

August 29, 2024

Study Completion Date

December 1, 2024

Conditions
PediatricGastroscopyED95Sedation
Interventions
DRUG

Remimazolam besylate and low-dose Esketamine

Esketamine was injected intravenously 0.25mg/kg and the initial dose of Remimazolam was 0.3mg/kg

DRUG

Remimazolam besylate and Medium dose Esketamine

Esketamine was injected intravenously 0.5mg/kg and the initial dose of Remimazolam was 0.2mg/kg

Trial Locations (1)

Unknown

The second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou

All Listed Sponsors
lead

Second Affiliated Hospital of Wenzhou Medical University

OTHER

NCT06303037 - Effect of Esketamine on 95% Induction Dose of Remimazolam | Biotech Hunter | Biotech Hunter